Oncogenic CMTM6 drives M2a macrophages formation and fuels cervical cancer progression

Bo Yin1, Chun Chen2, Baoyou Huang1,3

  • 1Department of Gynecology, Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai, China.

PubMed
Abstract

Insights

Exosomal CMTM6 drives immune suppression in cervical cancer by promoting M2a macrophage polarization and activating the mTOR pathway. This CMTM6/CD206/CCL2 axis worsens prognosis and offers a potential therapeutic target for cervical cancer immunotherapy.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • CMTM6 (CKLF like MARVEL transmembrane member 6) is implicated in cancer progression.
  • Its role in cervical cancer (CC) and the tumor microenvironment (TME) is not well understood.
  • CMTM6 may contribute to an immunosuppressive TME.

Purpose of the Study:

  • To investigate the expression and function of CMTM6 in cervical cancer.
  • To determine CMTM6's impact on macrophage polarization and the tumor microenvironment.
  • To explore CMTM6 as a potential prognostic biomarker and therapeutic target in CC.

Main Methods:

  • In vitro assays and mouse xenograft models were used to study CMTM6 in CC cells.
  • Macrophage polarization (M2a) and mTOR signaling pathway activation were evaluated.
  • Exosome secretion and uptake by macrophages were analyzed.

Main Results:

  • CMTM6 is encapsulated in exosomes secreted by CC cells and taken up by macrophages.
  • Exosomal CMTM6 induces M2a macrophage polarization and immunosuppressive pathways.
  • CMTM6 presence correlates with increased macrophage infiltration and poor prognosis in CC.
  • Exosomal CMTM6 activates mTOR signaling in macrophages, increasing CCL2 secretion, promoting M2a polarization and metastasis.

Conclusions:

  • Exosomal CMTM6 is a key driver of immune suppression in cervical cancer.
  • The CMTM6/CD206/CCL2 axis is linked to increased risk and unfavorable prognosis in CC patients.
  • Exosomal CMTM6 shows potential as a prognostic biomarker and therapeutic target for CC immunotherapy.

Related Concept Videos

Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
4.4K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.8K
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.7K